Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO: Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol. 2000, 35 (10): 1075-1081. 10.1080/003655200451207.
Article
CAS
PubMed
Google Scholar
Biank V, Broeckel U, Kugathasan S: Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm Bowel Dis. 2007, 13 (11): 1430-1438. 10.1002/ibd.20213.
Article
PubMed
Google Scholar
Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ: Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet. 2001, 357 (9272): 1925-1928. 10.1016/S0140-6736(00)05063-7.
Article
CAS
PubMed
Google Scholar
Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, Jahnsen J, Moum B, Klump B, Krawczak M: Association of NOD2 (CARD 15) genotype with clinical course of Crohn’s disease: a cohort study. Lancet. 2002, 359 (9318): 1661-1665. 10.1016/S0140-6736(02)08590-2.
Article
CAS
PubMed
Google Scholar
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O’Morain CA, Gassull M: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001, 411 (6837): 599-603. 10.1038/35079107.
Article
CAS
PubMed
Google Scholar
Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M: Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem. 2003, 278 (8): 5509-5512. 10.1074/jbc.C200673200.
Article
CAS
PubMed
Google Scholar
Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, Flavell RA: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005, 307 (5710): 731-734. 10.1126/science.1104911.
Article
CAS
PubMed
Google Scholar
Voss E, Wehkamp J, Wehkamp K, Stange EF, Schroder JM, Harder J: NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem. 2006, 281 (4): 2005-2011.
Article
CAS
PubMed
Google Scholar
Cosnes J, Beaugerie L, Carbonnel F, Gendre JP: Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001, 120 (5): 1093-1099. 10.1053/gast.2001.23231.
Article
CAS
PubMed
Google Scholar
Freeman HJ: Long-term prognosis of early-onset Crohn’s disease diagnosed in childhood or adolescence. Can J Gastroenterol. 2004, 18 (11): 661-665.
Article
PubMed
Google Scholar
Russell RK, Drummond HE, Nimmo EE, Anderson N, Smith L, Wilson DC, Gillett PM, McGrogan P, Hassan K, Weaver LT: Genotype-phenotype analysis in childhood-onset Crohn’s disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis. 2005, 11 (11): 955-964. 10.1097/01.MIB.0000183423.38037.f3.
Article
PubMed
Google Scholar
Lacher M, Helmbrecht J, Schroepf S, Koletzko S, Ballauff A, Classen M, Uhlig H, Hubertus J, Hartl D, Lohse P: NOD2 mutations predict the risk for surgery in pediatric-onset Crohn’s disease. J Pediatr Surg. 2010, 45 (8): 1591-1597. 10.1016/j.jpedsurg.2009.10.046.
Article
PubMed
Google Scholar
Walther F, Fusch C, Radke M, Beckert S, Findeisen A: Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J Pediatr Gastroenterol Nutr. 2006, 43 (1): 42-51. 10.1097/01.mpg.0000228105.91240.80.
Article
PubMed
Google Scholar
Tilg H, Moschen AR, Kaser A, Pines A, Dotan I: Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008, 57 (5): 684-694. 10.1136/gut.2006.117382.
Article
CAS
PubMed
Google Scholar
Cravo M, Guerreiro CS, dos Santos PM, Brito M, Ferreira P, Fidalgo C, Tavares L, Pereira AD: Risk factors for metabolic bone disease in Crohn’s disease patients. Inflamm Bowel Dis. 2010, 16 (12): 2117-2124. 10.1002/ibd.21297.
Article
PubMed
Google Scholar
Turk N, Cukovic-Cavka S, Korsic M, Turk Z, Vucelic B: Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn’s disease. Eur J Gastroenterol Hepatol. 2009, 21 (2): 159-166. 10.1097/MEG.0b013e3283200032.
Article
CAS
PubMed
Google Scholar
Agrawal M, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, Mechanick JI, Zaidi M: Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep. 2011, 9 (4): 251-257. 10.1007/s11914-011-0077-9.
Article
PubMed
Google Scholar
Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, Kugathasan S, Pfefferkorn M, Tolia V, Evans J: Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005, 41 (4): 416-421. 10.1097/01.mpg.0000183350.46795.42.
Article
PubMed
Google Scholar
Faulkner RA, Bailey DA, Drinkwater DT, McKay HA, Arnold C, Wilkinson AA: Bone densitometry in Canadian children 8–17 years of Age. Calcif Tissue Int. 1996, 59 (5): 344-351. 10.1007/s002239900138.
Article
CAS
PubMed
Google Scholar
Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B: Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995, 108 (2): 417-422. 10.1016/0016-5085(95)90068-3.
Article
CAS
PubMed
Google Scholar
Hoffmann JC, Preiss JC, Autschbach F, Buhr HJ, Hauser W, Herrlinger K, Hohne W, Koletzko S, Krieglstein CF, Kruis W: [Clinical practice guideline on diagnosis and treatment of Crohn’s disease]. Z Gastroenterol. 2008, 46 (9): 1094-1146. 10.1055/s-2008-1027796.
Article
CAS
PubMed
Google Scholar
Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005, 19 (Suppl A): 5-36.
Article
Google Scholar
de Ridder L, Weersma RK, Dijkstra G, van der Steege G, Benninga MA, Nolte IM, Taminiau JA, Hommes DW, Stokkers PC: Genetic susceptibility has a more important role in pediatric-onset Crohn’s disease than in adult-onset Crohn’s disease. Inflamm Bowel Dis. 2007, 13 (9): 1083-1092. 10.1002/ibd.20171.
Article
PubMed
Google Scholar
Sun L, Roesler J, Rosen-Wolff A, Winkler U, Koch R, Thurigen A, Henker J: CARD15 genotype and phenotype analysis in 55 pediatric patients with Crohn disease from Saxony, Germany. J Pediatr Gastroenterol Nutr. 2003, 37 (4): 492-497. 10.1097/00005176-200310000-00017.
Article
CAS
PubMed
Google Scholar
Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O’Morain C, Gassull M, Binder V: CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002, 70 (4): 845-857. 10.1086/339432.
Article
CAS
PubMed
PubMed Central
Google Scholar
Adler J, Rangwalla SC, Dwamena BA, Higgins PD: The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2011, 106 (4): 699-712. 10.1038/ajg.2011.19.
Article
CAS
PubMed
Google Scholar
Puntis J, McNeish AS, Allan RN: Long term prognosis of Crohn’s disease with onset in childhood and adolescence. Gut. 1984, 25 (4): 329-336. 10.1136/gut.25.4.329.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tomer G, Ceballos C, Concepcion E, Benkov KJ: NOD2/CARD15 variants are associated with lower weight at diagnosis in children with Crohn’s disease. Am J Gastroenterol. 2003, 98 (11): 2479-2484. 10.1111/j.1572-0241.2003.08673.x.
Article
CAS
PubMed
Google Scholar
Wine E, Reif SS, Leshinsky-Silver E, Weiss B, Shaoul RR, Shamir R, Wasserman D, Lerner A, Boaz M, Levine A: Pediatric Crohn’s disease and growth retardation: the role of genotype, phenotype, and disease severity. Pediatrics. 2004, 114 (5): 1281-1286. 10.1542/peds.2004-0417.
Article
PubMed
Google Scholar
Roesler J, Thurigen A, Sun L, Koch R, Winkler U, Laass MW, Gahr M, Rosen-Wolff A, Henker J: Influence of CARD15 mutations on disease activity and response to therapy in 65 pediatric Crohn patients from Saxony, Germany. J Pediatr Gastroenterol Nutr. 2005, 41 (1): 27-32. 10.1097/01.MPG.0000165017.00562.27.
Article
CAS
PubMed
Google Scholar
Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT: Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991, 32 (8): 913-917. 10.1136/gut.32.8.913.
Article
CAS
PubMed
PubMed Central
Google Scholar
Annese V, Lombardi G, Perri F, D’Inca R, Ardizzone S, Riegler G, Giaccari S, Vecchi M, Castiglione F, Gionchetti P: Variants of CARD15 are associated with an aggressive clinical course of Crohn’s disease–an IG-IBD study. Am J Gastroenterol. 2005, 100 (1): 84-92. 10.1111/j.1572-0241.2005.40705.x.
Article
CAS
PubMed
Google Scholar
Kugathasan S, Collins N, Maresso K, Hoffmann RG, Stephens M, Werlin SL, Rudolph C, Broeckel U: CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn’s disease. Clin Gastroenterol Hepatol. 2004, 2 (11): 1003-1009. 10.1016/S1542-3565(04)00452-5.
Article
CAS
PubMed
Google Scholar
Issenman RM, Atkinson SA, Radoja C, Fraher L: Longitudinal assessment of growth, mineral metabolism, and bone mass in pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr. 1993, 17 (4): 401-406. 10.1097/00005176-199311000-00012.
Article
CAS
PubMed
Google Scholar
Herzog D, Bishop N, Glorieux F, Seidman EG: Interpretation of bone mineral density values in pediatric Crohn’s disease. Inflamm Bowel Dis. 1998, 4 (4): 261-267.
CAS
PubMed
Google Scholar
Harpavat M, Greenspan SL, O’Brien C, Chang CC, Bowen A, Keljo DJ: Altered bone mass in children at diagnosis of Crohn disease: a pilot study. J Pediatr Gastroenterol Nutr. 2005, 40 (3): 295-300. 10.1097/01.MPG.0000153278.98861.32.
Article
PubMed
Google Scholar
von Tirpitz C, Steder-Neukamm U, Glas K, Sander S, Ring C, Klaus J, Reinshagen M: [Osteoporosis in inflammatory bowel disease - results of a survey among members of the German Crohn’s and Ulcerative Colitis Association]. Z Gastroenterol. 2003, 41 (12): 1145-1150.
Article
CAS
PubMed
Google Scholar
Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R, Cucchiara S: Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2007, 13 (4): 416-423. 10.1002/ibd.20039.
Article
PubMed
Google Scholar
Leonard MB: Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics. 2007, 119 (Suppl 2): S166-S174.
Article
PubMed
Google Scholar
Inohara N, Nunez G: NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol. 2003, 3 (5): 371-382. 10.1038/nri1086.
Article
CAS
PubMed
Google Scholar
Nemetz A, Toth M, Garcia-Gonzalez MA, Zagoni T, Feher J, Pena AS, Tulassay Z: Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut. 2001, 49 (5): 644-649. 10.1136/gut.49.5.644.
Article
CAS
PubMed
PubMed Central
Google Scholar
Niess JH, Klaus J, Stephani J, Pfluger C, Degenkolb N, Spaniol U, Mayer B, Lahr G, von Boyen GB: NOD2 Polymorphism Predicts Response to Treatment in Crohn’s Disease-First Steps to a Personalized Therapy. Dig Dis Sci. 2011, 57 (4): 879-886.
Article
PubMed
PubMed Central
Google Scholar
Weiss B, Lebowitz O, Fidder HH, Maza I, Levine A, Shaoul R, Reif S, Bujanover Y, Karban A: Response to medical treatment in patients with Crohn’s disease: the role of NOD2/CRAD15, disease phenotype, and age of diagnosis. Dig Dis Sci. 2010, 55 (6): 1674-1680. 10.1007/s10620-009-0936-8.
Article
CAS
PubMed
Google Scholar
Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D’Haens G: A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with −308 TNF gene polymorphism. Scand J Gastroenterol. 2002, 37 (7): 818-824.
Article
CAS
PubMed
Google Scholar
Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R: NOD2/CARD15 does not influence response to infliximab in Crohn’s disease. Gastroenterology. 2002, 123 (1): 106-111. 10.1053/gast.2002.34172.
Article
CAS
PubMed
Google Scholar
Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G: Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J Clin Gastroenterol. 2006, 40 (1): 55-63. 10.1097/01.mcg.0000190762.80615.d4.
Article
CAS
PubMed
Google Scholar